Core Biogenesis has launched Peaureva, an ingredient designed to address the biological causes of hair thinning and scalp ageing, at in-cosmetics Global stand 1H120.
The biotechnology-derived active has been shown to improve hair density in 28 days.
While many cosmetic haircare ingredients focus primarily on improving the appearance of hair fibre, Peaureva was developed to target the biological mechanisms that influence follicle activity and scalp health.
Hair thinning is increasingly understood as a multifactorial process driven by several biological changes in the scalp microenvironment.
Core Biogenesis identifies five biological drivers of scalp ageing that contribute to progressive hair density decline: hair cycle dysregulation; reduced dermal papilla signalling; declining microvascular support around follicles; progressive thinning of hair fibres; and deterioration of the scalp barrier environment.
Peaureva was designed to support these interconnected pathways using biomimetic growth factor technology stabilized with oleosomes.
Peaureva was evaluated in a randomized, single-blind, placebo-controlled clinical study involving 40 volunteers.
Instrumental measurements demonstrated statistically significant improvements compared with placebo across several scalp and hair parameters.
After 28 days, the active treatment showed:
• +33.6% increase in hair density
• +14.0% increase in the anagen/telogen ratio
• +5.0% increase in hair shaft thickness
• +17.5% increase in scalp hydration
The increase in the anagen/telogen ratio indicates a shift of follicles toward the active growth phase, while improvements in density and fiber thickness contribute to enhanced hair fullness.
Most cosmetic actives designed to address hair thinning typically require 90–120 days of continuous use to demonstrate modest improvements in hair density.
The early improvements observed with Peaureva highlight the potential of biotechnology-based approaches targeting follicular signalling pathways.
“Hair thinning is often treated as a cosmetic problem, but the underlying changes occur at the level of follicle biology and the scalp microenvironment,” said Tony Abboud, chief commercial officer at Core Biogenesis.
“With Peaureva, we are applying biomimetic growth factors and advanced delivery technology to support several biological drivers of scalp ageing simultaneously,” he added.
“These early clinical results illustrate how biotechnology may help redefine performance expectations for topical hair care ingredients.”
